All In Biotech

Drug Trial Radar · NCT06526182

A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis

A Phase 3, 2-Part, Open-Label and Double-Blind, Randomised Study to Evaluate the Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 520 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

520

Planned (sponsor's estimate)

Start

Jul 3, 2024

Primary completion

Apr 25, 2027

Study completion Apr 25, 2027

Sponsor

Lead sponsor
Almirall, S.A.Industry
Sponsor type
Industry
First posted
Jul 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to evaluate the effectiveness of 24 weeks of lebrikizumab in improving disease severity, signs, and symptoms in adults and adolescents with moderate-to-severe AD in Part 1 and to describe how similar is the current maintenance dosing regimen of lebrikizumab 250 mg every 4 weeks (Q4W) to the new proposed; lebrikizumab 500 mg every 12 weeks (Q12W), in terms of efficacy, safety, PK, ADA and blood biomarkers.

Conditions

  • Dermatitis, Atopic
  • Eczema

Interventions

  • LebrikizumabBiological

    Lebrikizumab solution for injection administered subcutaneously.

  • PlaceboOther

    Lebrikizumab Matching placebo solution for injection administered subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Percentage of Participants Achieving Eczema Area and Severity Index (EASI) Score Less than or Equal to (<=) 7 at Week 24Time frame: At Week 24
  2. Part 2: Percentage of Participants Achieving EASI 75 at Week 36Time frame: At Week 36
  3. Part 2: Percentage of Participants with an IGA Score of 0 or 1 and a Reduction >=2 PointsTime frame: From Baseline (Part 1) up to Week 36

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital General Universitario Dr. Balmis

    Alicante, Spain

  • Hospital del Mar - Parc de Salut Mar

    Barcelona, Spain

  • Hospital Universitario Clínico San Cecilio

    Granada, Spain

  • Consorci Hospital General Universitari de València

    Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.